Andrei Thomas-Tikhonenko Laboratory

Led by Andrei Thomas-Tikhonenko, PhD, researchers in the Thomas-Tikhonenko Laboratory are studying the effects of Myc oncogene-induced deregulation of microRNAs in hematopoietic malignancies and solid tumors such as pediatric neuroblastoma. The long-term goal of the work in the Thomas-Tikhonenko Laboratory is to define the contribution of Myc-induced deregulation of microRNAs to dysregulated neoplastic growth and to identify new targeted therapies to treat pediatric cancers and solid tumors.

Researchers Reveal How B-ALL Leukemia Tumors Resist Immunotherapy

Selected Publications

Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am J Hematol. 2017 Jan;92(1):E11-E13.
Yu H, Sotillo E, Harrington C, Wertheim G, Paessler M, Maude SL, Rheingold SR, Grupp SA, Thomas-Tikhonenko A1, Pillai V.


Convergence of acquired mutations and alternative splicing of CD19 confers resistance to CART-19 immunotherapy. Cancer Discov. 2015 Dec;5(12):1282-95. doi: 10.1158/2159-8290.CD-15-1020. Epub 2015 Oct 29.
Sotillo E, Barrett DM, Black KL, Bagashev A, Oldridge D, Wu G, Sussman R, Lanauze C, Ruella M, Gazzara MR, Martinez NM, Harrington CT, Chung EY, Perazzelli J, Hofmann TJ, Maude SL, Raman P, Barrera A, Gill S, Lacey SF, Melenhorst JJ, Allman D, Jacoby E, Fry T, Mackall C, Barash Y, Lynch KW, Maris JM, Grupp SA, Thomas-Tikhonenko A.


The importance of CD19 exon 2 for surface localization: closing the Ig-like loop. Blood. 2015 December; 126(23):3433.
Bagashev A, Sotillo E, Wu G, Thomas-Tikhonenko A.


Regulation of CD19 exon 2 inclusion in B-lymphoid cells by splicing factors and epigenetic marks. Blood. 2015 December; 126(23):2425.
Black K, Sotillo E, Martinez N, Gazzara M, Barrera A, Barash Y, Lynch K, Thomas-Tikhonenko A.


MYC and the art of microRNA maintenance. Cold Spring Harb Perspect Med. 2014 Apr 15;4(8).
Psathas JN, Thomas-Tikhonenko A.


Masking epistasis between MYC and TGFβ pathways in anti-angiogenesis mediated colon cancer suppressionJ Natl Cancer Inst. 2014 Apr;106(4):dju043. doi: 10.1093/jnci/dju043. Epub 2014 Mar 13.
Dews M, Tan GS, Hultine S, Raman P, Choi J, Duperret EK, Lawler J, Bass A, Thomas-Tikhonenko A.


The Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins: a novel lymphomagenic feed-forward loop. Blood. 2013 Dec 19;122(26):4220-9.
Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A.


Targeting of TGFβ signature and its essential component CTGF by miR-18 correlates with improved survival in glioblastoma. RNA. 2013 Feb;19(2):177-90.
Fox JL, Dews M, Minn AJ, Thomas-Tikhonenko A.


CD19 is a major B-cell receptor-independent activator of Myc-driven B-lymphomagenesis. J Clin Invest. 2012 Jun;122(6):2257-66.
Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A.


p53-responsive miR-194 inhibits thrombospondin-1 and promotes angiogenesis in colon cancers. Cancer Res. 2011 Dec 15;71(24):7490-501.
Sundaram P, Hultine S, Smith LM, Dews M, Fox JL, Biyashev D, Schelter JM, Huang Q, Cleary MA, Volpert OV, Thomas-Tikhonenko A.


The long reach of non-coding RNAs. Nat Genet. 2011 Jun 28;43(7):616-7.
Sotillo E, Thomas-Tikhonenko A.


Myc overexpression brings out unexpected anti-apoptotic effects of miR-34a. Oncogene. 2011 Jun 2;30(22):2587-94.
Sotillo E, Laver T, Mellert H, Schelter JM, Cleary MA, McMahon S, Thomas-Tikhonenko A.